Cephalon Sues Hetero Over Generic Leukemia Drug

Law360, New York (December 20, 2013, 3:25 PM ET) -- Cephalon Inc. filed suit in Delaware federal court Thursday alleging rival Hetero Labs Ltd.'s plans to manufacture a generic form of its cancer treatment Treanda violated a patent for the drug, the second infringement suit the Pennsylvania-based pharmaceuticals maker has brought over Treanda in two months.

Hetero's abbreviated new drug application to U.S. regulators seeking to market injectible bendamustine hydrochloride to treat chronic lymphocytic leukemia prior to the expiration of Cephalon's patents was unlawful, said the suit, asking the court to block the production of Hetero's...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required